Delivery type
Delivery by postal services, We will deliver, Other, International delivery
https://www.astersteroids.com/tirzepatide-a-new-dual-action-type-ii-diabetes-drug-showed-better-weight-loss-results-than-semaglultide/
Purity:98% HPLC
Packing:2mg/vial and 5mg/vial;10vials/box
Min Order: 1box
Payment:Bitcoin,Moneygram and Wester Union
Lead time:24hours after received payment
Safe shipping to US and most of Europe country
Storage:Shading, confined preservation,2-8°C
Tirzepatide is a drug approved for medical use in the United States, European Union, Canada and Australia for the treatment and control of type 2 diabetes mellitus. As a dual GIP and GLP-1 receptor agonist, it is the first of its kind.
What is Tirzepatide for Type 2 Diabetes?
The incidence of type 2 diabetes has been on the rise worldwide in recent years, with about 420 million adults worldwide, 30 million people in the United States and 114 million people in China having type 2 diabetes. Globally, one person dies every six seconds from complications related to type 2 diabetes. Type 2 diabetes is the eighth leading cause of death in the world.
Obesity and overweight are important risk factors for type 2 diabetes, and about 80-90% of type 2 diabetes patients are overweight or obese.
Type 2 diabetes mellitus, also known as non-insulin-dependent diabetes mellitus, is a chronic metabolic disease characterize by pancreatic beta cell dysfunction and insulin resistance. Treatment for this disease focuses on controlling blood sugar, improving insulin resistance and protecting pancreatic beta cell function. The main methods are insulin therapy, oral hypoglycemic drugs, diet control and exercise.
A number of drugs used to treat type 2 diabetes are GLP-1 agonists, including Wegovy, Ozempic (Semaglutide), Rybelsus, Saxenda, Trulicity(Dulaglutide) .Peptides Tirzepatide is the latest drugs to treat type 2 diabetes.
What is GLP-1?
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that promotes insulin secretion. It has the ability to reduce blood glucose levels in a glucose-dependent manner by enhancing insulin secretion.
Natural GLP-1 is usually secrete in the gut after eating. It is susceptible to amidation and proteolytic cleavage and is broken down rapidly in the body, resulting in a known half-life of about 2 minutes. As a result, only 10% to 15% of GLP-1 enters the cycle in its entirety. To overcome this problem, They develop GLP-1 receptor agonists to increase GLP-1 activity.
By activating GLP-1 receptor or prolonging the action time of GLP-1, GlP-1-based therapeutic drugs have the multi-effect mechanism of promoting β-cell generation and secretion of insulin, inhibiting α-cell secretion of glucagon, delaying gastric emptying and inhibiting appetite. To control blood sugar levels. At the same time, GLP is glucose-dependent and does not cause severe hypoglycemic symptoms.
What is Tirzepatide wight loss?
Tirzepatide basic information
Cas No.:2023788-19-2
MF:C225H348N48O68
MW: 4813.527
Bioavailability: 80%
Route of administration: subcutaneous
Elimination half-life: 5 days
Tirzepatide, also known as LY3298176, or Mounjaro, is a linear polypeptide composed of 39 amino acids that has been chemically modified by lipylation to improve its uptake into cells and metabolic stability. In structure, Tirzepatide is an analogue of GIP. Fatty acids are attached to the base of GIP, thus having a longer half-life and higher affinity with albumin.
Tirzepatide is a new type II diabetes drug. As an analog of GIP, Tirzepatide plays the similar role of GIP. At the same time, it is also a GLP-1 receptor agonist, which has the dual effects of lowering blood glucose and promoting gastrointestinal function, as well as promoting weight loss.
What is GIP?
GIP, glucose-dependent insulin promoting polypeptide, also known as Gastric inhibitory polypeptide, is a hormone that stimulates insulin release from the pancreas.
GIP also protects the small intestine from acid damage by reducing the secretion of stomach acid, reducing the speed at which food is transported through the stomach.
